Background
==========

Among all malignant tumors in the urinary system, renal cell carcinoma (RCC) is the second most common one, after bladder carcinoma. Because of its inherent insensitivity to radiation and chemotherapy, RCC is usually treated by surgical resection. However, as a result of distal metastasis or venous invasion, many patients are already unsuitable for radical surgery. Additionally, of patients with successful surgery, 20% to 40% experienced recurrence and/or metastasis. Therefore, the development of alternative treatment is still of critical importance.

Isothiocyanate is a glucosinolate hydrolysis product that consists of different types based on various side chains, and about one-third of them are allyl isothiocyanate (AITC). Glucosinolate widely exists in cruciferous plants, such as cabbage and cauliflower and their byproducts. Some studies suggest that AITC, as a tumor-related chemical compound found in natural plant diets, is involved in various biological processes, including cell apoptosis induction, cell cycle interference, or invasion/metastasis inhibition in various tumors, such as colon cancer, bladder carcinoma, liver cancer, neuroblastoma malignant glioma, and prostate carcinoma. Experiments on animal models found that AITC inhibited the progression of bladder carcinoma during the urine into bladder tissues. An epidemiological survey also indicated the improvement of the survival rate of patients with bladder cancer after eating cruciferous vegetables. Because RCC also belongs to the urinary system cancers, we thus hypothesized that AITC might also regulate the pathogenesis and progression of RCC. No direct animal study or clinical report, however, has been made regarding the treatment efficacy of AITC in RCC. In this context, we selected RCC cell line GRC-1 and examined the cell proliferation and apoptosis after the treatment with gradient concentrations of AITC. Also, the expressions of apoptotic-associated genes, *Bcl-2* and *Bax*, were also quantified, to elucidate the possible mechanism of AITC in RCC pathogenesis.

Material and Methods
====================

Cell culture
------------

Renal carcinoma cell line GRC-1 was purchased from the Institute of Urine, at Beijing Medical University. Cells were generated from a 40-year-old male patient with recurrent mixed cell carcinoma (mainly renal granular cell carcinoma) after left nephrectomy, pathological grading of G3. Cells were cultivated in RMPI1640 medium (Gibco, US) containing 10% fetal bovine serum (FBS; Gibco, US) in a humidified chamber with 5% CO~2~ at 37°C. Cells were passed every 2 to 3 days. Culture medium was first removed, then washed twice by phosphate buffered saline (PBS). Trypsin was added to digest cells for preparing single-cell suspensions, which were centrifuged at 1000 g for 5 min, and resuspended in 1-mL culture medium.

CCK8 proliferation assay
------------------------

The proliferation of cells was tested by cell counting with hemocytometer and Trypan Blue. Cells (1×10^4^) were seeded into 96-well plates for 12-hour acclimation. AITC gradient concentrations of 0, 7.5, 15, and 30 μM were added to experimental cells at different treatment times (24, 48, and 72 hours; n=5 each). After drug intervention, PBS was used to wash cells, followed by adding 0.1 mL CCK8 mixture (1: 10 dilution) and 2-hour incubation at 37°C. A microplate reader was then used to quantify absorbance value at 450 nm for calculating relative survival rate of cells:
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Flow cytometry
--------------

Cell suspensions were added into 6-well plates for 12-hour acclimation. Gradient concentrations of AITC (0, 7.5, 15, and 30 μM) were then used for 24-hour treatment in triplicates. After incubation, cells were digested by trypsin, washed in PBS, and centrifuged at 1000 *g* for 5 min. The proliferation of cells was tested by cell counting with hemocytometer. Cells (1×10^6^) were suspended, centrifuged, and resuspended in Annexin V-FITC binding buffer and propidium iodinate. After incubation in the dark for 20 min, the cell mixture was loaded for flow cytometry assay of apoptotic ratio.

Real time PCR
-------------

Total RNA was extracted by Trizol, and was quantified using ultraviolet spectrometer. RNA integrity was identified using 1% agarose gel electrophoresis. cDNA was synthesized using reverse transcription kit (Takara, Japan) following manual instruction. Real-time fluorescent quantitative PCR was performed in a cycler (Model ViiA7, ABI, US) using SYBR green mixture (Takara, Japan), with cDNA as the template. PCR conditions were: 95°C pre-denature for 10 min, followed by 40 cycles each consisting of 95°C denature for 15 sec, 60°C annealing for 60 sec, and 72°C elongation for 60 sec. Each experiment was performed in triplicates using β-actin as the internal reference.

Western blotting
----------------

After treatment with gradient AITC (0, 7.5, 15, and 30 μM) for 24 hours, cells were lysed and homogenized for extracting total protein in the supernatant. Coomasie Brilliant Blue staining was used to quantify protein level. Proteins were separated in SDS-PAGE and transferred to NC membrane under electrical field. The membrane was first blocked by 5% defatted milk powder for 2 hours, then washed in PBS. Primary antibody was added for overnight incubation, followed by washing and secondary antibody incubation (1 hour). ECL reagents were added to develop the membrane, which was then exposed under x-ray. GIS-2020D gel image analysis system was used to calculate optical density values of protein bands. Relative expression level was calculated against β-actin.

Statistical analysis
--------------------

SPSS 13.0 software was used to process all collected data, of which those fitted normal distribution was expressed as mean ± standard deviation. Analysis of variance was used to compare means across multiple groups, followed by least significant difference (LSD) test. *P*\<0.05 was considered statistically significant.

Results
=======

GRC-1 cell proliferation
------------------------

In the assay with different concentrations of AITC, the proliferation of GRC-1 cells was inhibited in both dose- and time-dependent manners. The treatment with 30 μM of AITC for 72 hours had the most potent effect ([Table 1](#t1-medscimonit-22-4283){ref-type="table"}).

GRC-1 cell apoptosis
--------------------

As shown in [Figure 1](#f1-medscimonit-22-4283){ref-type="fig"}, the apoptotic ratio of GRC-1 cells in control, 7.5-μM, 15-μM, and 30-μM groups were (7.08%±1.20), (13.28%±2.03), (19.46%±1.48), and (30.26%±1.58), respectively. The apoptotic ratio was increased by AITC in a dose-dependent manner.

Bax and Bcl-2 mRNA levels
-------------------------

The mRNA level of the *Bcl-2* gene gradually decreased in AITC-treated cells as compared with controls (*P*\<0.05). In contrast, the *Bax* mRNA level was up-regulated when concentration of AITC was increased ([Figure 2](#f2-medscimonit-22-4283){ref-type="fig"}).

Bax and Bcl-2 protein expression levels
---------------------------------------

Consistent with *Bax* and *Bcl-2* mRNA levels, the expression of Bcl-2 protein decreased as the concentration of AITC increased, whereas Bax protein level increased, indicating a decreasing Bcl-2/Bax ratio trend as AITC dosage increases ([Table 2](#t2-medscimonit-22-4283){ref-type="table"}, [Figure 3](#f3-medscimonit-22-4283){ref-type="fig"}).

Discussion
==========

At present, the treatment of RCC includes surgery, chemotherapy, radiotherapy, immunotherapy, and targeted therapy; however, in some cases, RCC is not sensitive to radiotherapy or chemotherapy. Moreover, surgical treatment is mainly used in patients with early metastasis of RCC, which restricts the application. Immunotherapy and targeting therapy remain to be further developed. Therefore, development of a novel treatment for RCC is of great importance. Because of fewer associated side effects, medical plants have shown promising antitumor profiles compared with classical chemotherapy drugs. Both *in vivo* and *in vitro* studies have proved the antitumor effect of isothiocyanate \[[@b18-medscimonit-22-4283],[@b19-medscimonit-22-4283]\]. AITC has been reported to inhibit the progression of bladder carcinoma \[[@b9-medscimonit-22-4283]\]. Because RCC and bladder carcinoma are both urinary system cancers, we investigated whether AITC also regulates the pathogenesis and progression of RCC.

Our results showed a growing dearth of GRC-1 cells with elevated AITC concentration in a time-dependent manner, among which, 30-μM AITC treatments for 72 hours had potent inhibitory effects on cell proliferation (32%). The higher dosage of AITC also induced more cell apoptosis after 24 hours' treatment, suggesting the inhibitory role of AITC may be owing to the induction of cell apoptosis. Evidence also revealed that AITC inhibited the RT4 cell proliferation by including cell apoptosis and interfering with cell cycle \[[@b10-medscimonit-22-4283]\].

Bax and Bcl-2 belong to Bcl-2 family, which can modulate cell apoptosis \[[@b20-medscimonit-22-4283]\]. Bcl-2 and Bax play as an antagonist pair. Bax itself promotes cell apoptosis and forms a dimer with Bcl-2 to limit the inhibitory effect of Bcl-2 on apoptosis \[[@b21-medscimonit-22-4283]\]. The elevation of the Bcl-2/Bax ratio, therefore, was observed during the suppression of cell apoptosis \[[@b22-medscimonit-22-4283]\], whereas the induction of apoptosis is always accompanied by the decline of the Bcl-2/Bax ratio \[[@b23-medscimonit-22-4283]\]. Our study determined the effect of AITC on the expressions of Bax and Bcl-2 and found elevated *Bax* gene expression as well as descending *Bcl-2* gene expression as the dosage of AITC increased, indicating a negative correlation between Bcl-2/Bax ratio and AITC concentration. Our results suggest that AITC inhibits the proliferation of GRC-1 cell line due to the imbalance between bcl2 and Bax, as is consistent with a previous study in RT4 cells \[[@b10-medscimonit-22-4283]\].

Conclusions
===========

For the first time, a study was performed on the effect of AITC on RCC cells, providing evidence of the inhibition on GRC-1 cell proliferation by AITC, possibly via Bcl-2/Bax imbalanced expression and further induced cell apoptosis. However, because the mechanism of AITC in inhibiting cell proliferation and inducing apoptosis is inherently complicated, the precise mechanism requires further explanation.
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###### 

AITC's effect on GRC-1 cell proliferation.

  AITC concentration   24 h                                                             48 h                                                             72 h
  -------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------
  0 μM                 1.00±0.042                                                       1.00±0.043                                                       1.00±0.041
  7.5 μM               0.92±0.038[\*](#tfn1-medscimonit-22-4283){ref-type="table-fn"}   0.87±0.038[\*](#tfn1-medscimonit-22-4283){ref-type="table-fn"}   0.81±0.040[\*](#tfn1-medscimonit-22-4283){ref-type="table-fn"}
  15 μM                0.86±0.044[\*](#tfn1-medscimonit-22-4283){ref-type="table-fn"}   0.78±0.039[\*](#tfn1-medscimonit-22-4283){ref-type="table-fn"}   0.69±0.043[\*](#tfn1-medscimonit-22-4283){ref-type="table-fn"}
  30 μM                0.72±0.057[\*](#tfn1-medscimonit-22-4283){ref-type="table-fn"}   0.67±0.041[\*](#tfn1-medscimonit-22-4283){ref-type="table-fn"}   0.58±0.042[\*](#tfn1-medscimonit-22-4283){ref-type="table-fn"}

p\<0.05 compared to 0 μM group.

###### 

Bax and Bcl-2 protein level after AITC treatment.

  Protein     0 μM        7.5 μM                                                          15 μM                                                           30 μM                                                           P value
  ----------- ----------- --------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- ---------
  Bax         0.41±0.04   0.48±0.05[\*](#tfn2-medscimonit-22-4283){ref-type="table-fn"}   0.63±0.04[\*](#tfn2-medscimonit-22-4283){ref-type="table-fn"}   0.72±0.06[\*](#tfn2-medscimonit-22-4283){ref-type="table-fn"}   \<0.001
  Bcl-2       0.82±0.05   0.75±0.04[\*](#tfn2-medscimonit-22-4283){ref-type="table-fn"}   0.69±0.06[\*](#tfn2-medscimonit-22-4283){ref-type="table-fn"}   0.50±0.05[\*](#tfn2-medscimonit-22-4283){ref-type="table-fn"}   \<0.001
  Bcl-2/Bax   2.00±0.14   1.56±0.15[\*](#tfn2-medscimonit-22-4283){ref-type="table-fn"}   1.10±0.11[\*](#tfn2-medscimonit-22-4283){ref-type="table-fn"}   0.69±0.12[\*](#tfn2-medscimonit-22-4283){ref-type="table-fn"}   \<0.001

p\<0.05 compared to 0 μM group.
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